Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
Table 2
Response to neoadjuvant imatinib (NAI).
Patient
Tumour site
Largest tumour diameter Before NAI (cm)
Largest tumour diameter After NAI (cm)
Change in tumour size (%)
Duration of NAI (months) and final dosage of imatinib (mg)
RECIST response
1
Rectum
2.5
2.2
−12.0
12 (600)
SDi
2
Stomach
8.3
5.9
−28.9
12 (600)
PRii
3
Stomach
4
1.5
−62.5
6 (400)
PR
4
Duodenum
13
6.4
−50.8
12 (400)
PR
5
Stomach
16.5
7
−57.6
12 (400)
PR
6
Stomach
8.7
3.5
−59.8
12 (400)
PR
7
Stomach
17.3
20.2
16.8
12 (600)
SD
8
Stomach
9.1
10
9.9
2 (600)
SD
9
Liver
1.7
1.3
−23.5
4 (600)
SD
10
Oesophagus
9.2
5.6
−39.1
12 (400)
PR
11
Duodenum
2.8
2.3
−17.9
12 (400)
SD
12
Stomach
4.3
3.2
−25.6
12 (600)
SD
13
Stomach
29
34
17.2
2.4 (600)
SD
14
Stomach
5.6
4.5
−19.6
6 (400)
SD
Miii
—
9.4
7.7
−25.2
9
SD
iSD: stable disease (less than 30% reduction or 20% increase in largest diameter).
iiPR: partial response (30% reduction or more in largest diameter).
iiiM: mean.
